Genomic and clinical predictors of lacosamide response in refractory epilepsies

Genomic and clinical predictors of lacosamide response in refractory epilepsies

Abstract Objective Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real‐world clinical setting. Methods We tested the association of clinical predictors with treatment response using regression modeling...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Sinéad B. Heavin, Mark McCormack, Stefan Wolking, Lisa Slattery, Nicole Walley, Andreja Avbersek, Jan Novy, Saurabh R. Sinha, Rod Radtke, Colin Doherty, Pauls Auce, John Craig, Michael R. Johnson, Bobby P. C. Koeleman, Roland Krause, Wolfram S. Kunz, Anthony G. Marson, Terence J. O'Brien, Josemir W. Sander, Graeme J. Sills, Hreinn Stefansson, Pasquale Striano, Federico Zara, EPIGEN Consortium, EpiPGX Consortium, Chantal Depondt, Sanjay Sisodiya, David Goldstein, Holger Lerche, Gianpiero L. Cavalleri, Norman Delanty
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Wiley 2019-12-01
Cyfres:Epilepsia Open
Pynciau:
GWAS
lacosamide
pharmacogenomics
pharmacoresistance
refractory
Mynediad Ar-lein:https://doi.org/10.1002/epi4.12360

Rhyngrwyd

https://doi.org/10.1002/epi4.12360

Eitemau Tebyg